. | AMPK activity (units/mg protein) . | . | . | ||
---|---|---|---|---|---|
Treatment . | AMPK α1 . | AMPK α2 . | AMPK α1 and α2 . | ||
Basal | 0.11±0.01 | 0.003±0.001 | 0.13±0.02 | ||
5 mM sodium azide | 0.98±0.15 | 0.015±0.002 | 1.08±0.12 | ||
500 μM AICAR | 0.56±0.11 | 0.011±0.005 | 0.61±0.13 | ||
0.4 M sorbitol | 0.32±0.04 | 0.008±0.005 | 0.31±0.03 |
. | AMPK activity (units/mg protein) . | . | . | ||
---|---|---|---|---|---|
Treatment . | AMPK α1 . | AMPK α2 . | AMPK α1 and α2 . | ||
Basal | 0.11±0.01 | 0.003±0.001 | 0.13±0.02 | ||
5 mM sodium azide | 0.98±0.15 | 0.015±0.002 | 1.08±0.12 | ||
500 μM AICAR | 0.56±0.11 | 0.011±0.005 | 0.61±0.13 | ||
0.4 M sorbitol | 0.32±0.04 | 0.008±0.005 | 0.31±0.03 |
Clone 9 cells in triplicate dishes were exposed to 5 mM sodium azide, 500μM AICAR or 0.4 M sorbitol for 60 minutes. AMPK α1 and/or AMPKα2 were then immunoprecipitated from cell lysates with the relevant antibodies, and the immunocomplexes were assayed for their ability to phosphorylate the AMARA peptide as described in the Materials and Methods. The data shown are means±s.e.m for three experiments.